ARTICLE | Company News

Genzyme metabolic news

January 18, 2010 8:00 AM UTC

Genzyme began shipments of newly-produced Fabrazyme agalsidase beta made at its Allston, Mass. manufacturing plant. The company said that it is meeting about 30% of patient demand for the Fabry's disease treatment, but said in its presentation at the JP Morgan Healthcare Conference in San Francisco that it is on track to meet 80-100% of demand in 2Q10. ...